InterPAD - DETAILS

Palbociclib, 571190-30-2, PD-0332991, Ibrance, PD0332991, PD 0332991, UNII-G9ZF61LE7G, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one, Palbociclib free base, G9ZF61LE7G, CHEBI:85993, PD 332991, 571190-30-2 (free base), MFCD11840850, 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one, Palbociclib(PD0332991), LQQ, Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-, 2euf, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO(PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, Palbociclib [USAN], PD-332991, 571190-30-2 pound not827022-32-2, Palbociclib [USAN:INN], palbociclibum, [d8]-Palbociclib, Ibrance (TN), Palbociclib- Bio-X, Kinome_3823, Kinome_3824, PALBOCICLIB [MI], 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one hydrochloride, PALBOCICLIB [INN], PALBOCICLIB [JAN], Palbociclib (JAN/USAN), PALBOCICLIB [WHO-DD], 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one, SCHEMBL462630, BDBM6309, CHEMBL189963, GTPL7380, PD 0332991 (Palbociclib), DTXSID40972590, EX-A408, L01XE33, PALBOCICLIB [ORANGE BOOK], 2euf; PD 0332991, AHJRHEGDXFFMBM-UHFFFAOYSA-N, OTAVA-BB 1115529, BCPP000125, HMS3265M09, HMS3265M10, HMS3265N09, HMS3265N10, HMS3744G13, AMY14886, BCP09274, BCP18381, NSC758247, NSC772256, NSC800815, PD 991, s4482, AKOS022205241, BCP9001058, DB09073, NSC-758247, NSC-772256, NSC-800815, SB40426, Pyrido-[2,3-d]-pyrimidin-7-one 43, NCGC00263129-01, NCGC00263129-08, NCGC00263129-21, NCGC00263129-22, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one, AC-25485, AS-17016, BP166224, HY-50767, SY026143, A8153, NS00069617, D10372, EN300-18531248, PD 0332991,PD0332991, BRD-K51313569-001-01-1, Q15269707, Z2216894329, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[6,5-d]pyrimidin-7-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)-pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one, 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one

No.	Title	Href
1	Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma. Cancer Biol Med. 2021 Feb 15;18(1):227-244. doi: 10.20892/j.issn.2095-3941.2020.0186.	`Click`
2	Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo. Cell Cycle. 2021 Dec;20(23):2494-2506. doi: 10.1080/15384101.2021.1991121.	`Click`

No.

Title

Href

Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma. Cancer Biol Med. 2021 Feb 15;18(1):227-244. doi: 10.20892/j.issn.2095-3941.2020.0186.

Click

Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo. Cell Cycle. 2021 Dec;20(23):2494-2506. doi: 10.1080/15384101.2021.1991121.

Click

Name	Palbociclib
PubChem CID	5330286
Molecular Weight	447.5g/mol
Synonyms	Palbociclib, 571190-30-2, PD-0332991, Ibrance, PD0332991, PD 0332991, UNII-G9ZF61LE7G, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one, Palbociclib free base, G9ZF61LE7G, CHEBI:85993, PD 332991, 571190-30-2 (free base), MFCD11840850, 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one, Palbociclib(PD0332991), LQQ, Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-, 2euf, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO(PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE, 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, Palbociclib [USAN], PD-332991, 571190-30-2 pound not827022-32-2, Palbociclib [USAN:INN], palbociclibum, [d8]-Palbociclib, Ibrance (TN), Palbociclib- Bio-X, Kinome_3823, Kinome_3824, PALBOCICLIB [MI], 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one hydrochloride, PALBOCICLIB [INN], PALBOCICLIB [JAN], Palbociclib (JAN/USAN), PALBOCICLIB [WHO-DD], 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one, SCHEMBL462630, BDBM6309, CHEMBL189963, GTPL7380, PD 0332991 (Palbociclib), DTXSID40972590, EX-A408, L01XE33, PALBOCICLIB [ORANGE BOOK], 2euf; PD 0332991, AHJRHEGDXFFMBM-UHFFFAOYSA-N, OTAVA-BB 1115529, BCPP000125, HMS3265M09, HMS3265M10, HMS3265N09, HMS3265N10, HMS3744G13, AMY14886, BCP09274, BCP18381, NSC758247, NSC772256, NSC800815, PD 991, s4482, AKOS022205241, BCP9001058, DB09073, NSC-758247, NSC-772256, NSC-800815, SB40426, Pyrido-[2,3-d]-pyrimidin-7-one 43, NCGC00263129-01, NCGC00263129-08, NCGC00263129-21, NCGC00263129-22, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one, AC-25485, AS-17016, BP166224, HY-50767, SY026143, A8153, NS00069617, D10372, EN300-18531248, PD 0332991,PD0332991, BRD-K51313569-001-01-1, Q15269707, Z2216894329, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[6,5-d]pyrimidin-7-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)-pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one, 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one
Drug Type	Small molecule
Formula	C₂₄H₂₉N₇O₂
SMILES	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChI	1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChIKey	AHJRHEGDXFFMBM-UHFFFAOYSA-N
CAS Number	571190-30-2
ChEMBL ID	CHEMBL189963
ChEBI ID	CHEBI:85993
TTD ID	D00UZR
Drug Bank ID	DB09073
KEGG ID	D10372
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Nobiletin, Palbociclib
Partner Name	Nobiletin
Disease Info	[ICD-11: 2C90.0]	Renal cell carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Phosphorylation	CDK2	hsa1017
	Down-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Phosphorylation	RB1	hsa5925
	Down-regulation	Expression	SKP2	hsa6502
In Vivo Model	A total of 2×10⁶ 786-O cells were mixed 1:1 with Matrigel (BD Biosciences) in a total volume of 200 μL, and were injected subcutaneously into the right flank side of nude mice.
Result	Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma

Pair Name	Polyphyllin I, Palbociclib
Partner Name	Polyphyllin I
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CCNE1	hsa898
	Down-regulation	Phosphorylation	CDK2	hsa1017
	Down-regulation	Phosphorylation	CDK4	hsa1019
	Down-regulation	Phosphorylation	CDK6	hsa1021
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Phosphorylation	RB1	hsa5925
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vitro Model	NCI-H460	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0459
In Vivo Model	A549 cells (3×10⁶) in 0.2 mL medium were injected subcutaneously into the right flank of each nude mice.
Result	We first time demonstrated PPI can disturb CDK2 function through upregulation of p21. The PPI effect on CDK2 provides a choice for a chemotherapeutic strategy for the elimination of NSCLC. Our study highlighted the clinical significance of simultaneously blocking of CDK2 and CDK4/6 for NSCLC treatment.